

**LISTING OF CLAIMS:**

1 Claim 1. (Original) A process for the production of  $\alpha$ -interferon comprising the steps:

- i) inducing of human leukocytes by means of a virus,
- ii) treating the leukocytes with an enhancing agent selected from
  - a) xanthine, pyrimidinol and pyrimidinone, theophylline, theobromine, enprophylline, hypoxanthine, 8-phenyltheophylline, 2-amino-5-bromo-6-methylpyrimidinol, 2-amino-6-methyl-4-pyrimidinol and thymine;
  - b) an organic solvent selected from the group consisting of non-aromatic ketones, aliphatic or cyclic amides, alkylated aliphatic or cyclic urea derivatives and aliphatic or cyclic sulfoxides; or a combination of the compounds from a) with an organic solvent from b).

9  
Claim 2. (Original) A process according to claim 1, characterized in that the leukocytes are monocytes.

7  
Claim 3. (Previously Presented) A process according to claim 1, characterized in that the enhancing agent is added at the same time or up to 4 hours after the virus induction.

2  
Claim 4. (Previously Presented) A process according to claim 1, characterized in that the virus is Sendai virus.

<sup>4</sup>  
Claim ~~5~~. (Previously Presented) A process according to claim 1, characterized in that the enhancing agent is theophylline.

Claim 6. (Withdrawn) A process according to claim 1, characterized in that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 7. (Withdrawn) A process according to claim 1, characterized in that the enhancing agent is thymine.

<sup>5</sup>  
Claim ~~8~~. (Currently Amended) A process according to claim 1, characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2-pentanone, N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and N,N-dimethylacetamide.

<sup>6</sup> <sup>5</sup>  
Claim ~~9~~. (Original) A process according to claim ~~8~~, characterized in that the solvent is N-methyl-2-pyrrolidinone.

<sup>10</sup> <sup>9</sup>  
Claim ~~10~~. (Previously Presented) A process according to claim ~~2~~, characterized in that the enhancing agent is added at the same time or up to 4 hours after the virus induction.

12

Claim ~~11~~. (Previously Presented) A process according to claim ~~2~~,<sup>9</sup>

characterized in that the virus is Sendai virus.

8

Claim ~~12~~. (Previously Presented) A process according to claim ~~3~~,<sup>7</sup>

characterized in that the virus is Sendai virus.

11

Claim ~~13~~. (Previously Presented) A process according to claim 10,

characterized in that the virus is Sendai virus.

13

Claim ~~14~~. (Previously Presented) A process according to claim 2,<sup>9</sup>

characterized in that the enhancing agent is theophylline.

9

Claim ~~15~~. (Previously Presented) A process according to claim ~~3~~,<sup>7</sup>

characterized in that the enhancing agent is theophylline.

3

Claim ~~16~~. (Previously Presented) A process according to claim ~~4~~,<sup>2</sup>

characterized in that the enhancing agent is theophylline.

Claim 17. (Withdrawn) A process according to claim 2, characterized in that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 18. (Withdrawn) A process according to claim 3, characterized in that the enhancing agent is 2-amino-5-bromo-6-methyl-4-pyrimidinol.

Claim 19. (Withdrawn) A process according to claim 2, characterized in that the enhancing agent is thymine.

<sup>14</sup>  
Claim 20. (Currently Amended) A process according to claim <sup>9</sup>2,  
characterized in that the organic solvent is any of acetone, 2-butanone, 1,3-dimethyl-  
2-imidazolidinone, dimethylsulfoxide, N-ethyl-2-pyrrolidinone, 4-methyl-2-pentanone,  
N-methyl-2-pyrrolidinone, 2-pyrrolidinone, tetramethylene sulfoxide or and  
N,N-dimethylacetamide.